Mitsios John V, Tambaki Afroditi P, Abatzis Morfis, Biris Nikolaos, Sakarellos-Daitsiotis Maria, Sakarellos Constantinos, Soteriadou Ketty, Goudevenos John, Elisaf Moses, Tsoukatos Demokritos, Tsikaris Vassilios, Tselepis Alexandros D
Department of Chemistry Medical School, University of Ioannina, Greece.
Eur J Biochem. 2004 Feb;271(4):855-62. doi: 10.1111/j.1432-1033.2004.03990.x.
The platelet integrin receptor alphaIIbbeta3 plays a critical role in thrombosis and haemostasis by mediating interactions between platelets and several ligands but primarily fibrinogen. It has been shown previously that the YMESRADR KLAEVGRVYLFL (313-332) sequence of the alphaIIb subunit plays an important role in platelet activation, fibrinogen binding and alphaIIbbeta3-mediated outside-in signalling. Furthermore, we recently showed that the 20-residue peptide (20-mer) alphaIIb 313-332, is a potent inhibitor of platelet aggregation and fibrinogen binding to alphaIIbbeta3, interacting with fibrinogen rather than the receptor. In an effort to determine the sequence and the minimum length required for the biological activity of the above 20-mer, we synthesized seven octapeptides, each overlapping by six residues, covering the entire sequence and studied their effect on platelet activation as well as fibrinogen binding to activated platelets. We show for the first time that octapeptides containing the RAD sequence are capable of inhibiting platelet aggregation and secretion as well as fibrinogen binding to the activated alphaIIbbeta3, possibly interacting with the ligand rather than the receptor. This suggests that the RAD sequence, common to all the inhibitory peptides, is critical for their biological activity. However, the presence of the YMES sequence, adjacent to RAD, significantly increases the peptide's biological potency. The development of such inhibitors derived from the 313-332 region of the alphaIIb subunit may be advantageous against the RGD-like antagonists as they could inhibit platelet activation without interacting with alphaIIbbeta3, thus failing to further induce alphaIIbbeta3-mediated outside-in signalling.
血小板整合素受体αIIbβ3通过介导血小板与多种配体(主要是纤维蛋白原)之间的相互作用,在血栓形成和止血过程中发挥关键作用。先前已表明,αIIb亚基的YMESRADR KLAEVGRVYLFL(313 - 332)序列在血小板活化、纤维蛋白原结合以及αIIbβ3介导的外向内信号传导中起重要作用。此外,我们最近发现,20个氨基酸的肽段(20肽)αIIb 313 - 332是血小板聚集和纤维蛋白原与αIIbβ3结合的有效抑制剂,它与纤维蛋白原相互作用而非与受体相互作用。为了确定上述20肽生物活性所需的序列和最小长度,我们合成了7个八肽,每个八肽相互重叠6个残基,覆盖整个序列,并研究了它们对血小板活化以及纤维蛋白原与活化血小板结合的影响。我们首次表明,含有RAD序列的八肽能够抑制血小板聚集和分泌以及纤维蛋白原与活化的αIIbβ3结合,可能是与配体而非受体相互作用。这表明所有抑制性肽共有的RAD序列对其生物活性至关重要。然而,与RAD相邻的YMES序列的存在显著增强了肽的生物活性。源自αIIb亚基313 - 332区域的此类抑制剂的开发可能优于RGD样拮抗剂,因为它们可以在不与αIIbβ3相互作用的情况下抑制血小板活化,从而不会进一步诱导αIIbβ3介导的外向内信号传导。